DGAP-News

Biotest AG: Biotest reaches 2nd milestone in Biotest Next Level expansion project

DGAP-News: Biotest AG / Key word(s): Miscellaneous Biotest AG: Biotest reaches 2nd milestone in Biotest Next Level expansion project 22.06.2017 / 07:00 The issuer is solely responsible for the content of this announcement. / PRESSEMITTEILUNG Biotest reaches 2nd milestone in Biotest Next Level expansion project

- Authorities grant building approval

- Relocation activities of laboratories and offices for production start in June

 

Dreieich, 22 June, 2017. Within the Biotest Next Level expansion project, Biotest will more than double its production capacity at the Dreieich site, invest over EUR 250 million and create around 300 new jobs. After completion of the shell construction of Biotest Next Level in October 2015, the second milestone was reached within the schedule with the building approval. This is a further step towards the complete commissioning of the new plant, which will start the regular operation in approximately 2 to 3 years and will still result in a considerable financial burden during its ramp-up.

The permit for the use of the building is the result of an intensive examination by the building inspectorate of the district of Offenbach (Bauaufsicht des Kreises Offenbach).

A prerequisite was, among other things, proof that the systems work perfectly in respect to safety, such as fire alarm systems, fire extinguishers and alarm systems - particularly the interaction of all technical components. Apart from the commitment of the entire project team, the key to success was the detailed planning of the preparations and the tests to be carried out in collaboration with authorities and experts.

As a result of the approval, relocation activities in the laboratory as well as the production offices will be carried out as planned in June 2017.

"By reaching this milestone, we have made a decisive step forward in achieving the goals of the company, and on behalf of the entire Board, I would like to thank the whole team for the great performance." stated Bernhard Ehmer, CEO of Biotest AG.